Nasui Wang1,2, Alvin W K Tan1,3, Linda A Jahn1, Lee Hartline1, James T Patrie4, Shaoda Lin2, Eugene J Barrett1, Kevin W Aylor1, Zhenqi Liu5. 1. Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA. 2. Department of Endocrinology and Metabolism, Shantou University First Hospital, Guangdong, China. 3. Department of Endocrinology, Tan Tock Seng Hospital, Singapore. 4. Department of Public Health Sciences, University of Virginia Health System, Charlottesville, VA. 5. Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA zl3e@virginia.edu.
Abstract
OBJECTIVE: Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND METHODS: Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS: Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ∼30% and ∼40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ∼20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS: In obese humans with microvascular insulin resistance, GLP-1's vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.
OBJECTIVE: Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obesehumans. RESEARCH DESIGN AND METHODS: Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS:Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ∼30% and ∼40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ∼20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS: In obesehumans with microvascular insulin resistance, GLP-1's vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.
Authors: Lucy H Clerk; Michelle A Vincent; Linda A Jahn; Zhenqi Liu; Jonathan R Lindner; Eugene J Barrett Journal: Diabetes Date: 2006-05 Impact factor: 9.461
Authors: Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: Clin Sci (Lond) Date: 2014-08 Impact factor: 6.124
Authors: Timothy M Hughes; Andrew D Althouse; Nancy A Niemczyk; Marquis S Hawkins; Allison L Kuipers; Kim Sutton-Tyrrell Journal: Cardiovasc Diabetol Date: 2012-09-22 Impact factor: 9.951
Authors: Alvin W K Tan; Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; James T Patrie; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: J Endocr Soc Date: 2018-01-22
Authors: William B Horton; Linda A Jahn; Lee M Hartline; Kevin W Aylor; James T Patrie; Eugene J Barrett Journal: J Physiol Date: 2021-02-02 Impact factor: 5.182
Authors: Layla A Abushamat; P Mason McClatchey; Rebecca L Scalzo; Irene Schauer; Amy G Huebschmann; Kristen J Nadeau; Zhenqi Liu; Judith G Regensteiner; Jane E B Reusch Journal: J Endocr Soc Date: 2020-06-07
Authors: Kaitlin M Love; Linda A Jahn; Lee M Hartline; James T Patrie; Eugene J Barrett; Zhenqi Liu Journal: Sci Rep Date: 2021-06-01 Impact factor: 4.379
Authors: Kaitlin M Love; Eugene J Barrett; Steven K Malin; Jane E B Reusch; Judith G Regensteiner; Zhenqi Liu Journal: J Mol Cell Biol Date: 2021-10-21 Impact factor: 6.216
Authors: Katherine M Roberts-Thomson; Lewan Parker; Andrew C Betik; Glenn D Wadley; Paul A Della Gatta; Thomas H Marwick; Michelle A Keske Journal: J Physiol Date: 2022-02-01 Impact factor: 6.228